Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA

NCT01055496 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01055496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
March 31, 2014
Enrollment
103 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell